Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ex-BMS Exec Sugita Tapped as President of Nxera Pharma Japan
Nxera Pharma, formerly known as Sosei Group or Sosei Heptares, said on October 1 that it has appointed 20-year pharma industry veteran Makoto Sugita as president of Nxera Pharma Japan. Sugita, who most recently was the R&D head of Bristol…
To read the full story
Related Article
BUSINESS
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Hodogaya Chemical Sets Up Nucleic Acid CDMO Subsidiary
September 4, 2026
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…